Welcome to our dedicated page for Clene SEC filings (Ticker: CLNNW), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Clene's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Clene's regulatory disclosures and financial reporting.
CLNN reports multiple proposed and executed sales of Common Stock by Symbiosis II LLC as disclosed on Form 144. The filing lists numerous open-market dispositions on dated entries, including 31,297 shares on 03/31/2026 for $152,316.52 and 32,705 shares on 01/12/2026 for $179,867.17. Transactions are shown across January–March 2026 with individual trade sizes and cash amounts reported per line item.
CLNN reports multiple proposed and executed sales of Common Stock by Symbiosis II LLC as disclosed on Form 144. The filing lists numerous open-market dispositions on dated entries, including 31,297 shares on 03/31/2026 for $152,316.52 and 32,705 shares on 01/12/2026 for $179,867.17. Transactions are shown across January–March 2026 with individual trade sizes and cash amounts reported per line item.
CLNN affiliate submitted a Form 144 notice to sell 477,000 shares of Common Stock.
The filing lists multiple recent open‑market dispositions by Symbiosis II LLC from 12/22/2025 through 02/03/2026, with per‑trade share counts and gross proceeds reported for each trade.
CLNN affiliate submitted a Form 144 notice to sell 477,000 shares of Common Stock.
The filing lists multiple recent open‑market dispositions by Symbiosis II LLC from 12/22/2025 through 02/03/2026, with per‑trade share counts and gross proceeds reported for each trade.
Clene Inc. is a clinical-stage pharmaceutical company focused on clean-surfaced nanocrystal (CSN) therapeutics targeting neurodegenerative diseases such as ALS, multiple sclerosis, and Parkinson’s disease. Its lead asset, CNM-Au8, is an orally delivered gold nanocrystal suspension designed to boost cellular energy and reduce oxidative stress.
The company reports extensive preclinical and Phase 1–2 data suggesting neuroprotective, remyelinating, and biomarker effects, including NAD+/ATP increases and reduced neurofilament light chain in ALS. Clene is pursuing an accelerated approval pathway for CNM-Au8 in ALS, aiming to submit an NDA by June 2026 and planning a Phase 3 RESTORE-ALS trial as a confirmatory study, subject to funding.
Clene Inc. is a clinical-stage pharmaceutical company focused on clean-surfaced nanocrystal (CSN) therapeutics targeting neurodegenerative diseases such as ALS, multiple sclerosis, and Parkinson’s disease. Its lead asset, CNM-Au8, is an orally delivered gold nanocrystal suspension designed to boost cellular energy and reduce oxidative stress.
The company reports extensive preclinical and Phase 1–2 data suggesting neuroprotective, remyelinating, and biomarker effects, including NAD+/ATP increases and reduced neurofilament light chain in ALS. Clene is pursuing an accelerated approval pathway for CNM-Au8 in ALS, aiming to submit an NDA by June 2026 and planning a Phase 3 RESTORE-ALS trial as a confirmatory study, subject to funding.
Clene Inc. filed an 8-K after issuing a stockholder letter that maps out 2026 milestones for its ALS drug candidate CNM-Au8 and its funding plan. The company completed an oversubscribed registered direct offering of over $28 million, with an initial tranche of over $6 million expected to fund operations into the fourth quarter of 2026. Two additional tranches totaling over $22 million are structured around potential FDA NDA acceptance and approval milestones and are expected to support operations into 2027. Clene plans an in-person Type C FDA meeting by the end of the first quarter of 2026, aims to submit a New Drug Application for CNM-Au8 via an accelerated pathway in the second quarter of 2026, and sees potential for FDA acceptance, a PDUFA decision date, and possible 2027 commercial launch. The letter highlights survival and biomarker data in ALS, a favorable safety profile over more than 1,000 patient years, and plans to start the confirmatory Phase 3 RESTORE-ALS trial later in 2026.
Clene Inc. filed an 8-K after issuing a stockholder letter that maps out 2026 milestones for its ALS drug candidate CNM-Au8 and its funding plan. The company completed an oversubscribed registered direct offering of over $28 million, with an initial tranche of over $6 million expected to fund operations into the fourth quarter of 2026. Two additional tranches totaling over $22 million are structured around potential FDA NDA acceptance and approval milestones and are expected to support operations into 2027. Clene plans an in-person Type C FDA meeting by the end of the first quarter of 2026, aims to submit a New Drug Application for CNM-Au8 via an accelerated pathway in the second quarter of 2026, and sees potential for FDA acceptance, a PDUFA decision date, and possible 2027 commercial launch. The letter highlights survival and biomarker data in ALS, a favorable safety profile over more than 1,000 patient years, and plans to start the confirmatory Phase 3 RESTORE-ALS trial later in 2026.
Clene Inc. director Reed N. Wilcox reported an equity award in the form of stock options. He was granted options covering 3,306 shares of common stock under the Clene Inc. Amended 2020 Stock Plan at an exercise price of $4.73 per share.
The options vest immediately upon grant, giving him the right to purchase these shares at the stated exercise price. Following this grant, his directly held derivative securities position from this option award is reported as 3,306 options.
Clene Inc. director Reed N. Wilcox reported an equity award in the form of stock options. He was granted options covering 3,306 shares of common stock under the Clene Inc. Amended 2020 Stock Plan at an exercise price of $4.73 per share.
The options vest immediately upon grant, giving him the right to purchase these shares at the stated exercise price. Following this grant, his directly held derivative securities position from this option award is reported as 3,306 options.
Clene Inc. director David J. Matlin received a stock option grant covering 5,372 shares of Common Stock. The option was granted on February 19, 2026 under the Clene Inc. Amended 2020 Stock Plan at an exercise price of $4.73 per share and vests immediately upon grant.
Clene Inc. director David J. Matlin received a stock option grant covering 5,372 shares of Common Stock. The option was granted on February 19, 2026 under the Clene Inc. Amended 2020 Stock Plan at an exercise price of $4.73 per share and vests immediately upon grant.
Clene Inc. director Jacobovitz Shalom reported receiving a stock option grant for 4,098 shares of common stock. The option was granted on February 19, 2026 under the Clene Inc. Amended 2020 Stock Plan at an exercise price of $4.73 per share.
The option vests immediately upon grant, meaning it is fully exercisable right away. Following this award, Shalom holds stock options for 4,098 shares, all reported as directly owned. This is a compensation-related equity grant rather than an open-market share purchase.
Clene Inc. director Jacobovitz Shalom reported receiving a stock option grant for 4,098 shares of common stock. The option was granted on February 19, 2026 under the Clene Inc. Amended 2020 Stock Plan at an exercise price of $4.73 per share.
The option vests immediately upon grant, meaning it is fully exercisable right away. Following this award, Shalom holds stock options for 4,098 shares, all reported as directly owned. This is a compensation-related equity grant rather than an open-market share purchase.
Clene Inc. director Jonathon Gay reported receiving a grant of stock options. The award covers 3,271 shares of Common Stock, granted on February 19, 2026 under the Clene Inc. Amended 2020 Stock Plan at an exercise price of $4.73 per share. The options vest immediately upon grant, and Gay now directly holds 3,271 stock options following this acquisition.
Clene Inc. director Jonathon Gay reported receiving a grant of stock options. The award covers 3,271 shares of Common Stock, granted on February 19, 2026 under the Clene Inc. Amended 2020 Stock Plan at an exercise price of $4.73 per share. The options vest immediately upon grant, and Gay now directly holds 3,271 stock options following this acquisition.
Clene Inc. director Matthew Kiernan received a grant of stock options covering 2,755 shares of common stock. The options were granted on February 19, 2026 under the Clene Inc. Amended 2020 Stock Plan at an exercise price of $4.73 per share and vest immediately upon grant.
Clene Inc. director Matthew Kiernan received a grant of stock options covering 2,755 shares of common stock. The options were granted on February 19, 2026 under the Clene Inc. Amended 2020 Stock Plan at an exercise price of $4.73 per share and vest immediately upon grant.
Clene Inc. insider Symbiosis II LLC has filed a notice to sell 60,842 shares of CLNN common stock. The planned sale, through Merrill Lynch on Nasdaq around 01/29/2026, has an aggregate market value of $265,731, compared with 10,333,980 shares outstanding.
The shares were acquired on 06/20/2023 via an open-market purchase for cash. The filing also lists numerous prior open-market sales by Symbiosis II LLC from December 2025 through January 29, 2026, with gross proceeds disclosed for each trade. The seller represents it is not aware of undisclosed material adverse information about Clene.
Clene Inc. insider Symbiosis II LLC has filed a notice to sell 60,842 shares of CLNN common stock. The planned sale, through Merrill Lynch on Nasdaq around 01/29/2026, has an aggregate market value of $265,731, compared with 10,333,980 shares outstanding.
The shares were acquired on 06/20/2023 via an open-market purchase for cash. The filing also lists numerous prior open-market sales by Symbiosis II LLC from December 2025 through January 29, 2026, with gross proceeds disclosed for each trade. The seller represents it is not aware of undisclosed material adverse information about Clene.